Next 10 |
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
2024-06-28 09:29:56 ET More on AbbVie, Genmab, etc. AbbVie: 5 Reasons That Make A Buy Case AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie buys bowel...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...
2024-06-27 08:15:04 ET BTIG analyst issues BUY recommendation for GMAB on June 27, 2024 07:34AM ET. The previous analyst recommendation was Buy. GMAB was trading at $25.67 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst re...
2024-06-27 05:34:44 ET Genmab ( GMAB ) and partner AbbVie ( NYSE: ABBV ) have received U.S. FDA approval for their monoclonal antibody Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma.... Read the full article ...
Company Announcement Approval based on results from Phase 1/2 EPCORE ® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL EPKINLY offers an off-the-shelf, T-cell engaging treatment option that ...
2024-06-24 12:56:10 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it’s important to save money and invest for the future. At the same time, in...
2024-06-07 09:16:13 ET More on Halozyme Therapeutics Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics ...
2024-06-06 12:51:08 ET More on Halozyme Therapeutics Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...